表纸
市场调查报告书

心律不整治疗药的全球市场:2019年~2023年

Global Cardiac Arrhythmias Therapeutics Market 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品编码 900601
出版日期 内容资讯 英文 130 Pages
订单完成后即时交付
价格
Back to Top
心律不整治疗药的全球市场:2019年~2023年 Global Cardiac Arrhythmias Therapeutics Market 2019-2023
出版日期: 2019年07月29日内容资讯: 英文 130 Pages
简介

全球心律不整治疗药市场,2018年,口服心律不整治疗药的低成本、可用性、无痛、徐放效果等成为要素,口服药市场区隔获得很大的市场占有率,预计这个趋势在预测期间也将持续。还有该市场,预计血栓症的盛行率增加,正确的诊断方法的利用可能性,心血管疾病相关意识的高涨等成为成长促进因素,在预测期间内预计将以4%以上的年复合成长率扩大。但,心律不整治疗药相关的黑盒警示,替代产品的可得性,严格的法规环境,可能妨碍在预测期间内心律不整治疗药产业的成长。

本报告提供全球心律不整治疗药市场相关调查分析,市场规模及成长率,市场趋势,市场的推动要素与课题,市场机会验证,再加上主要供应商等相关的系统性资讯。

目录

第1章 摘要整理

第2章 调查范围

  • 简介1
  • 简介2
  • 美金的货币换算比率

第3章 市场情形

  • 市场生态系统
  • 市场特征
  • 市场区隔分析

第4章 市场规模

  • 市场定义
  • 市场规模(2018年)
  • 市场规模及预测(2018年~2023年)

第5章 波特的五力分析

  • 买主谈判力
  • 供应商谈判力
  • 新加入厂商的威胁
  • 替代品的威胁
  • 竞争对手的威胁
  • 市场情况

第6章 市场区隔:各应用领域

  • 市场区隔:各应用领域
  • 各应用领域比较:市场规模及预测(2018年~2023年)
  • 口服药
  • 静脉注射
  • 市场机会:各应用领域

第7章 客户形势

第8章 各地区形势

  • 各地区市场区隔
  • 各地区比较:市场规模及预测(2018年~2023年)
  • 北美
  • 欧洲
  • 亚洲
  • 其他地区
  • 主要国家
  • 市场机会

第9章 决策架构

第10章 成长要素与课题

  • 市场成长要素
  • 市场课题

第11章 市场趋势

  • 控制AF的心律的基因治疗的登场
  • 可早期发现心律不整的技术进步
  • 供应商的研究开发努力的发展

第12章 业者情势

  • 概要
  • 创造性破坏状况
  • 竞争方案

第13章 供应商分析

  • 交易厂商
  • 供应商分类
  • 供应商的市场定位
  • Bayer AG
  • Eli Lilly and Co.
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Sanofi

第14章 附录

  • 调查方法
  • 简称的清单
  • 供应商的市场定位定义

第15章 关于TECHNAVIO

目录
Product Code: IRTNTR31782

About this market

Cardiac arrhythmias therapeutics are pharmaceutical agents that are used to normalize the issue of cardiac arrhythmia. Technavio's cardiac arrhythmias therapeutics market analysis considers sales from both oral and intravenous applications. Our analysis also considers the sales of cardiac arrhythmias therapeutics in North America, Europe, Asia and the rest of the world (ROW). In 2018, the oral segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as Low cost, easy to consume, no pain, extended-release effect of oral arrhythmias therapeutics will play a significant role in the oral segment to maintain its market position. Also, our global cardiac arrhythmias therapeutics market report also looks at factors such as the growing prevalence of thrombosis, availability of precise diagnostic methods, rising awareness about cardiovascular diseases. However, black box warning associated with cardiac arrhythmias therapeutics, availability of substitute products, stringent regulatory environment may hamper the growth of the cardiac arrhythmias therapeutics industry over the forecast period.

Overview

Availability of precise diagnostic methods

The availability of precise diagnostic methods, like electrocardiogram (ECG) Hotter monitors, event monitors, stress IQ tests, echocardiogram, cardiac catheterization, electrophysiology study (EPS), and head-up tiff table tests have led to increase in the diagnosis rate of cardiac arrhythmias, thus contributing to increased prescription of therapeutics for cardiac arrhythmias. Such factors will lead to the expansion of the global cardiac arrhythmias therapeutics market at a CAGR of over 4% during the forecast period.

The advent of gene therapy to control ventricular rate in AF

The current treatment therapy for AF involves the use of antiarrhythmic drugs to sustain the sinus rhythm or drugs that can curb the conduction in the atrioventricular (AV) node in order to control the ventricular rate. The medication therapy used for the treatment of arrhythmia exerts its pharmacological effect by targeting the conduction properties of the AV node- by suppressing the calcium current or by altering the cholinergic and adrenergic tone. Therefore, the global cardiac arrhythmias therapeutics market presents an urgent need for the development of biological drugs, which can target the gene and thus, improve cardiac functioning. Ongoing research in this area is expected to have a positive impact on market growth during the forecast period.

For the detailed list of factors that will drive the global cardiac arrhythmias therapeutics market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of several major players, the global cardiac arrhythmias therapeutics market is fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading cardiac arrhythmias therapeutics manufacturers, that include Bayer AG, Eli Lilly and Co., GlaxoSmithKline Plc, Pfizer Inc., and Sanofi.

Also, the cardiac arrhythmias therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY APPLICATION

  • Market segmentation by application
  • Comparison by application
  • Oral - Market size and forecast 2018-2023
  • Intravenous - Market size and forecast 2018-2023
  • Market opportunity by application

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • The advent of gene therapy to control ventricular rate in AF
  • Technological advances enabling the early detection of cardiac arrhythmias
  • Growing R&D efforts by vendors

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bayer AG
  • Eli Lilly and Co.
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Sanofi

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Product overview
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Application - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by application
  • Exhibit 20: Oral - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Oral - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Intravenous - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Intravenous - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Market opportunity by application
  • Exhibit 25: Customer landscape
  • Exhibit 26: Market share by geography 2018-2023 (%)
  • Exhibit 27: Geographic comparison
  • Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 30: Top 3 countries in North America
  • Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Top 3 countries in Europe
  • Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Top 3 countries in Asia
  • Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 39: Top 3 countries in ROW
  • Exhibit 40: Key leading countries
  • Exhibit 41: Market opportunity
  • Exhibit 42: Diagnostic methods
  • Exhibit 43: Side-effects of cardiac arrhythmias therapeutics
  • Exhibit 44: Substitute products to cardiac arrhythmias therapeutics
  • Exhibit 45: Impact of drivers and challenges
  • Exhibit 46: Vendor landscape
  • Exhibit 47: Landscape disruption
  • Exhibit 48: Vendors covered
  • Exhibit 49: Vendor classification
  • Exhibit 50: Market positioning of vendors
  • Exhibit 51: Bayer AG - Vendor overview
  • Exhibit 52: Bayer AG - Business segments
  • Exhibit 53: Bayer AG - Organizational developments
  • Exhibit 54: Bayer AG - Geographic focus
  • Exhibit 55: Bayer AG - Segment focus
  • Exhibit 56: Bayer AG - Key offerings
  • Exhibit 57: Bayer AG - Key customers
  • Exhibit 58: Eli Lilly and Co. - Vendor overview
  • Exhibit 59: Eli Lilly and Co. - Business segments
  • Exhibit 60: Eli Lilly and Co. - Organizational developments
  • Exhibit 61: Eli Lilly and Co. - Geographic focus
  • Exhibit 62: Eli Lilly and Co. - Segment focus
  • Exhibit 63: Eli Lilly and Co. - Key offerings
  • Exhibit 64: Eli Lilly and Co. - Key customers
  • Exhibit 65: GlaxoSmithKline Plc - Vendor overview
  • Exhibit 66: GlaxoSmithKline Plc - Business segments
  • Exhibit 67: GlaxoSmithKline Plc - Organizational developments
  • Exhibit 68: GlaxoSmithKline Plc - Geographic focus
  • Exhibit 69: GlaxoSmithKline Plc - Segment focus
  • Exhibit 70: GlaxoSmithKline Plc - Key offerings
  • Exhibit 71: GlaxoSmithKline Plc - Key customers
  • Exhibit 72: Pfizer Inc. - Vendor overview
  • Exhibit 73: Pfizer Inc. - Business segments
  • Exhibit 74: Pfizer Inc. - Organizational developments
  • Exhibit 75: Pfizer Inc. - Geographic focus
  • Exhibit 76: Pfizer Inc. - Segment focus
  • Exhibit 77: Pfizer Inc. - Key offerings
  • Exhibit 78: Pfizer Inc. - Key customers
  • Exhibit 79: Sanofi - Vendor overview
  • Exhibit 80: Sanofi - Business segments
  • Exhibit 81: Sanofi - Organizational developments
  • Exhibit 82: Sanofi - Geographic focus
  • Exhibit 83: Sanofi - Segment focus
  • Exhibit 84: Sanofi - Key offerings
  • Exhibit 85: Sanofi - Key customers
  • Exhibit 86: Validation techniques employed for market sizing
  • Exhibit 87: Definition of market positioning of vendors
Back to Top